



## GUIDELINE

# Acute Respiratory Tract Infection

<b>Scope (Staff):</b>	Medical, Nursing, Pharmacy
<b>Scope (Area):</b>	All Clinical areas

### Child Safe Organisation Statement of Commitment

CAHS commits to being a child safe organisation by applying the National Principles for Child Safe Organisations. This is a commitment to a strong culture supported by robust policies and procedures to reduce the likelihood of harm to children and young people.

This document should be read in conjunction with this [disclaimer](#)

Prior to initiation of antibiotic therapy, microbiology samples should be taken as appropriate. Empiric therapy should be modified once diagnostic tests are available. This guideline gives information on the appropriate duration of antibiotic therapy. Consider [IV to oral switch](#) to complete the course of antibiotics as required. A Biofire Respiratory Multiplex PCR should be sent on all admitted patients with a suspected respiratory tract infection.

CLINICAL SCENARIO		Usual duration	DRUGS/DOSES			
			Standard Protocol	Known or Suspected MRSA <sup>a</sup>	Low Risk Penicillin allergy <sup>b</sup>	High Risk Penicillin allergy <sup>b</sup>
Community Acquired pneumonia (CAP)	All CAP < 4 weeks of age	7 days	IV gentamicin <sup>c</sup> <b>AND</b> IV benzylpenicillin (dose as per <a href="#">neonatal guidelines</a> )	As per standard protocol	IV cefotaxime <sup>d</sup> (dose as per <a href="#">neonatal guidelines</a> )	Discuss with Infectious Diseases
	CAP (mild to moderate) ≥ 4 weeks of age	3 to 5 days (IV and oral)	Oral <a href="#">amoxicillin</a> 25 mg/kg/dose (to a maximum of 1 gram) 8 hourly	As per standard protocol	Oral <a href="#">cefuroxime</a> <sup>e</sup> or consider amoxicillin challenge in discussion with immunology	Oral <a href="#">azithromycin</a> <sup>f</sup> <b>OR</b> Oral <a href="#">doxycycline</a> <sup>g</sup>
			If intolerant to oral therapy, IV <a href="#">benzylpenicillin</a> 50 mg/kg/dose (to a maximum of 1.2 grams) 6 hourly	As per standard protocol	IV <a href="#">ceftriaxone</a> <sup>h</sup>	Discuss with Infectious Diseases

CLINICAL SCENARIO		Usual duration	DRUGS/DOSES			
			Standard Protocol	Known or Suspected MRSA <sup>a</sup>	Low Risk Penicillin allergy <sup>b</sup>	High Risk Penicillin allergy <sup>b</sup>
Community Acquired pneumonia (CAP)	CAP (severe) ≥ 4 weeks of age requiring intensive care admission, fluid bolus ≥ 20 mL/kg, or hypoxia (<85% in air)	Up to 7 days (IV and oral)	IV <a href="#">ceftriaxone</a> 50 mg/kg/dose (to a maximum of 2 grams) once daily <b>AND</b> IV <a href="#">vancomycin</a> <sup>i</sup> 15 mg/kg/dose (to a maximum initial dose of 750 mg) 6 hourly	As per standard protocol		Discuss with Infectious Diseases
			The Biofire Respiratory Multiplex PCR is a rapid PCR test. <b>IF</b> positive for atypical organisms ( <i>Bordetella pertussis</i> , <i>Bordetella parapertussis</i> , <i>Chlamydia pneumoniae</i> or <i>Mycoplasma pneumoniae</i> ) <b>ADD</b> IV/oral <a href="#">azithromycin</a> 10 mg/kg/dose (to a maximum of 500 mg) once daily for up to 5 days  <b>IF</b> the PCR is positive for Influenza A or Influenza B <b>ADD</b> Oral <a href="#">oseltamivir</a> 3mg /kg/dose (to a maximum of 75 mg) twice daily for five days Refer to ChAMP monograph for suggested dose bands. For empiric oral switch therapy, see mild to moderate CAP			
	CAP (with empyema or parapneumonic effusion) ≥ 4 weeks of age	variable	IV <a href="#">ceftriaxone</a> 50 mg/kg/dose (to a maximum of 2 grams) once daily	<b>ADD</b> IV <a href="#">vancomycin</a> <sup>i</sup> to standard protocol	As per standard protocol	IV <a href="#">ciprofloxacin</a> <sup>i</sup> <b>AND</b> IV <a href="#">vancomycin</a> <sup>i</sup>
			In the setting of severe CAP with empyema, see CAP (severe). If diagnostic sampling is not deemed safe or feasible, discuss with Infectious Diseases. In confirmed pneumococcal empyema, IV benzylpenicillin with switch to oral <a href="#">amoxicillin</a> is recommended (excluding patients with a <a href="#">high risk allergy</a> to penicillin or amoxicillin). Refer to <a href="#">Clinical Practice Guidelines: Pleural empyema</a>			
	CAP: Aspiration pneumonia ≥ 4 weeks of age	7 days (IV and oral)	Oral <a href="#">amoxicillin</a> 25 mg/kg/dose (to a maximum of 1 gram) 8 hourly	As per standard protocol	Oral <a href="#">cefuroxime</a> <sup>e</sup> or consider amoxicillin challenge in discussion with immunology	Oral <a href="#">azithromycin</a> <sup>f</sup>
			If intolerant to oral therapy, IV <a href="#">benzylpenicillin</a> 50 mg/kg/dose (to a maximum of 1.2 grams) 6 hourly	As per standard protocol		Discuss with Infectious Diseases

CLINICAL SCENARIO		Usual duration	DRUGS/DOSES			
			Standard Protocol	Known or Suspected MRSA <sup>a</sup>	Low Risk Penicillin allergy <sup>b</sup>	High Risk Penicillin allergy <sup>b</sup>
CAP: Severe Aspiration pneumonia requiring intensive care admission, fluid bolus ≥ 20mL/kg or hypoxia (<85% in air) ≥ 4 weeks of age	7 days (IV and oral)	IV <a href="#">amoxicillin/clavulanic acid</a> <sup>k</sup>	Discuss with Infectious Diseases	IV <a href="#">ceftriaxone</a> <sup>h</sup> <b>AND</b> IV <a href="#">metronidazole</a> <sup>l</sup>	Discuss with Infectious Diseases	
		For empiric oral step down therapy, use oral <a href="#">amoxicillin/clavulanic acid</a> 25 mg/kg/dose (to a maximum of 875 mg amoxicillin component) 12 hourly	Discuss with Infectious Diseases	Oral <a href="#">cefuroxime</a> <sup>e</sup> or consider amoxicillin challenge in discussion with immunology	Oral <a href="#">clindamycin</a> <sup>l</sup>	
Hospital Acquired Pneumonia	7 days (IV or oral)	Oral <a href="#">amoxicillin/clavulanic acid</a> 25 mg/kg/dose (to a maximum of 875 mg amoxicillin component) 12 hourly <b>OR</b> IV <a href="#">ceftriaxone</a> 50 mg/kg/dose (to a maximum of 2 grams) once daily	As per standard protocol	Oral <a href="#">cefuroxime</a> <sup>e</sup> or consider amoxicillin challenge in discussion with immunology	Discuss with Infectious Diseases	
		IV <a href="#">piperacillin/tazobactam</a> 100 mg/kg/dose (to a maximum of 4 grams piperacillin component) 8 hourly	As per standard protocol	IV <a href="#">cefepime</a> <sup>n</sup>	Discuss with Infectious Diseases	
	varies	IV <a href="#">piperacillin/tazobactam</a> 100 mg/kg/dose (to a maximum of 4 grams piperacillin component) 8 hourly <b>AND</b> IV <a href="#">vancomycin</a> 15 mg/kg/dose (to a maximum initial dose of 750 mg) 6 hourly	As per standard protocol	IV <a href="#">cefepime</a> <sup>n</sup> <b>AND</b> IV <a href="#">vancomycin</a> <sup>i</sup>	Discuss with Infectious Diseases	
For empiric oral step down therapy, use oral <a href="#">amoxicillin/clavulanic acid</a> 25 mg/kg/dose (to a maximum of 875 mg amoxicillin component) 12 hourly		Discuss with Infectious Diseases	Oral <a href="#">cefuroxime</a> <sup>e</sup> or consider amoxicillin challenge in discussion with immunology	Discuss with Infectious Diseases		

CLINICAL SCENARIO		Usual duration	DRUGS/DOSES			
			Standard Protocol	Known or Suspected MRSA <sup>a</sup>	Low Risk Penicillin allergy <sup>b</sup>	High Risk Penicillin allergy <sup>b</sup>
Atypical infections	Confirmed pertussis < 6 months old	5 days	Oral <a href="#">azithromycin</a> 10 mg/kg/dose (to a maximum of 500 mg) once daily  The Biofire Respiratory Multiplex PCR is a rapid PCR test. Only commence therapy if a positive result is reported.  Refer to <a href="#">Medical prophylaxis guideline</a> and <a href="#">Communicable Diseases Network Australia: Pertussis</a> for information on prophylaxis indications			
	Confirmed pertussis ≥ 6 months old	5 days	Oral <a href="#">azithromycin</a> 10 mg/kg/dose (to a maximum of 500 mg) on day 1 then 5 mg/kg (maximum 250 mg) once daily for 4 days  The Biofire Respiratory Multiplex PCR is a rapid PCR test. Only commence therapy if a positive result is reported.  Refer to <a href="#">Medical prophylaxis guideline</a> and <a href="#">Communicable Diseases Network Australia: Pertussis</a> for information on prophylaxis indications			
	Confirmed mycoplasma pneumoniae ≥ 4 weeks of age	3 days	<i>Mycoplasma pneumoniae</i> pneumonia is usually self-limiting. The benefit of antibiotic therapy is unclear. <b>Consider:</b> Oral <a href="#">azithromycin</a> 10 mg/kg/dose (to a maximum of 500 mg) once daily <b>OR</b> Oral <a href="#">doxycycline</a> Child < 21kg: 2.2mg/kg (to a maximum of 50mg) given 12 hourly Child ≥ 21kg to <26kg: 50 mg given 12 hourly Child ≥ 26kg to <35kg: 75 mg given 12 hourly Child ≥ 35kg: 100 mg given 12 hourly			
Influenza	Influenza (confirmed or probable) requiring hospitalisation (≥ 4 weeks of age)	5 days	Oral <a href="#">oseltamivir</a> 3 mg/kg/dose (to a maximum of 75 mg per dose) twice daily. Refer to ChAMP monograph for suggested dose bands  Note: consider therapy for CAP (as per standard protocol) if coexisting bacterial pneumonia suspected			

CLINICAL SCENARIO		Usual duration	DRUGS/DOSES			
			Standard Protocol	Known or Suspected MRSA <sup>a</sup>	Low Risk Penicillin allergy <sup>b</sup>	High Risk Penicillin allergy <sup>b</sup>
Influenza	Influenza (confirmed) not requiring hospitalisation (≥ 4 weeks of age)	5 days	IF risk factors for severe disease give oral <a href="#">oseltamivir</a> 3 mg/kg/dose (to a maximum of 75 mg per dose) twice daily. IF no risk factors, oseltamivir is not required. Refer to ChAMP monograph for suggested dose bands.			
	Refer to <a href="#">Medical prophylaxis guideline</a> for information on influenza prophylaxis Individuals at higher risk of poor outcomes with flu (adapted TG – Figure 2.41)					
	Influenza (confirmed or probable) (< 4 weeks of age)		- Chronic cardiac disease - Chronic respiratory conditions - Severe neurological conditions - Immunocompromised - Down Syndrome - Obesity - Other chronic illness - Residents of long-term residential facilities			
			Discuss with Infectious Diseases			
	SARS-CoV-2 COVID-19		Refer to: <a href="#">Clinical care of paediatric patients with COVID-19</a>  Discuss patients ≥ 12 years and ≥ 40 kg with significant immunocompromise and/or multiple risk factors for severe disease who are unvaccinated or under-vaccinated as antiviral therapy may be considered.			

- a) Children known or suspected to be colonised with MRSA may need to have their therapy/prophylaxis modified. Children suspected of having MRSA include:
  - i. Children previously colonised with MRSA
  - ii. Household contacts of MRSA colonised individuals
  - iii. In children who reside in regions with higher MRSA rates (e.g. Kimberley, Pilbara and Goldfields) a lower threshold for suspected MRSA should be given
  - iv. Children with recurrent skin infections or those unresponsive to ≥ 48 hours of beta-lactam therapy. For further advice, discuss with Microbiology or ID service.
- b) Refer to the [ChAMP Beta-lactam Allergy Guideline](#):
  - Low risk allergy: a delayed rash (>1hr after initial exposure) without mucosal or systemic involvement (without respiratory distress and/or cardiovascular compromise).
  - High risk allergy: an immediate rash (<1hr after exposure); anaphylaxis; severe cutaneous adverse reaction {e.g. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) and Stevens – Johnson syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)} or other severe systemic reaction.
- c) Gentamicin is rapidly bactericidal and should be administered prior to benzylpenicillin. Aminoglycoside antibiotics may be inactivated by penicillin and cephalosporin antibiotics; lines should be flushed well with a compatible fluid between administration.
- d) IV cefotaxime dose as per [neonatal guidelines](#)
- e) Oral [cefuroxime](#) **3 months or older: 15 mg/kg/dose** (to a maximum of 500mg) twice daily.  
 Suspension has recently been discontinued, where possible round to the nearest portion of a tablet or discuss with ChAMP or pharmacy for alternative options
- f) Oral [azithromycin](#) **10 mg/kg/dose** (to a maximum of 500mg) once daily
- g) Oral [doxycycline](#)  
 Child < 21kg: 2.2mg/kg (to a maximum of 50mg) given 12 hourly



Child ≥ 21kg to <26kg: 50 mg given 12 hourly  
 Child ≥ 26kg to <35kg: 75 mg given 12 hourly  
 Child ≥ 35kg: 100 mg given 12 hourly

- h) IV [ceftriaxone](#) **50 mg/kg/dose** (to a maximum of 2 grams) once daily
- i) IV [vancomycin](#) **15 mg/kg/dose** (to a maximum initial dose of 750 mg) 6 hourly. Therapeutic drug monitoring is required.
- j) IV [ciprofloxacin](#) **10 mg/kg/dose** (to a maximum of 400mg) given 12 hourly.
- k) IV [amoxicillin/clavulanic acid \(doses based on amoxicillin component\)](#):  
 Birth (term) to 3 months and < 4 kg: IV infusion 25 mg/kg/dose every 12 hours.  
 Birth (term) to 3 months and > 4kg: IV infusion 25 mg/kg/dose every 8 hours.  
 > 3 months and < 40 kg: IV 25 mg/kg/dose (maximum 1 gram) every 8 hours; increase to every 6 hours in severe infections.  
 > 40 kg: IV 1 gram every 8 hours; increase to every 6 hours in severe infections. Up to 2 grams every 6-8 hours can be used.
- l) IV [metronidazole](#) **12.5 mg/kg/dose** (to a maximum of 500 mg) 12 hourly
- m) Oral [clindamycin](#) **10 mg/kg/dose** (to a maximum of 450 mg) 8 hourly
- n) IV [cefepime](#) **50 mg/kg/dose** (to a maximum of 2 grams) 8 hourly

Related CAHS internal policies, procedures and guidelines
<a href="#">Antimicrobial Stewardship Policy</a>
<a href="#">ChAMP empiric guidelines and monographs</a>
<a href="#">Neonatal Medication Protocols</a>
<a href="#">Pleural empyema</a>

References and related external legislation, policies, and guidelines
<ol style="list-style-type: none"> <li>1. Antibiotic Writing Group. Therapeutic Guidelines - Antibiotic. West Melbourne: Therapeutic Guidelines Ltd; 2022. Available from: <a href="https://tgldcdp-tg-org-au.pklibresources.health.wa.gov.au/etgAccess">https://tgldcdp-tg-org-au.pklibresources.health.wa.gov.au/etgAccess</a>.</li> <li>2. McMullan BJ, Andresen D, Blyth CC, Avent ML, Bowen AC, Britton PN, et al. Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines. Lancet Infect Dis. 2016;16(e139-52).</li> </ol>

This document can be made available in alternative formats on request.

File Path:	<a href="W:\Safety &amp; Quality\CAHS\CLOVERS MEDICAL Pharmacy\Procedures Protocols and Guidelines\ChAMP\Word\Empiric Guidelines\PCH Templated (ED Guidelines)"><u>W:\Safety &amp; Quality\CAHS\CLOVERS MEDICAL Pharmacy\Procedures Protocols and Guidelines\ChAMP\Word\Empiric Guidelines\PCH Templated (ED Guidelines)</u></a>		
Document Owner:	Head of Department – Infectious Diseases		
Reviewer / Team:	Children’s Antimicrobial Management Program (ChAMP)		
Date First Issued:	August 2013	Last Reviewed:	November 2024
Amendment Dates:	November 2019, February 2021, April 2023, August 2023, October 2024	Next Review Date:	November 2027
Approved by:	Medication Safety Committee	Date:	November 2024
Endorsed by:	Chair, Drug and Therapeutics Committee	Date:	November 2024
Standards Applicable:	NSQHS Standards:  NSMHS: N/A Child Safe Standards: N/A		
<b>Printed or personally saved electronic copies of this document are considered uncontrolled</b>			
 <h2 style="margin: 0;">Healthy kids, healthy communities</h2> <div style="display: flex; justify-content: space-around; align-items: center;"> <span style="background-color: #4CAF50; color: white; padding: 2px 10px; border-radius: 15px;">Compassion</span> <span style="background-color: #FF9800; color: white; padding: 2px 10px; border-radius: 15px;">Excellence</span> <span style="background-color: #9C27B0; color: white; padding: 2px 10px; border-radius: 15px;">Collaboration</span> <span style="background-color: #F44336; color: white; padding: 2px 10px; border-radius: 15px;">Accountability</span> <span style="background-color: #395468; color: white; padding: 2px 10px; border-radius: 15px;">Equity</span> <span style="background-color: #8BC34A; color: white; padding: 2px 10px; border-radius: 15px;">Respect</span> </div> <p style="font-size: small; margin: 0;">Neonatology   Community Health   Mental Health   Perth Children’s Hospital</p>			